The impact of cyclosporine on the development of immunosuppressive therapy-pediatric transplantation using cyclosporine

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S197-S202

  Hoyer, P F ^a   Vester, U ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

BONE DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROEMULSION; NEPHROTOXICITY; PEDIATRIC SURGERY; PRIORITY JOURNAL; RECIPIENT; REVIEW; STUNTING SYNDROME;

EID: 1642273029     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.051     Document Type: Article

References (47)

1. Fine R.N., Malekzadeh M.H., Pennisi A.J., et al. Renal retransplantation in children. J Pediatr. 95:1979;244.
2. Broyer M., Gagnadoux M.F., Guest G., et al. Kidney transplantation in children results of 383 grafts performed at Enfants Malades Hospital from 1973 to 1984. Adv Nephrol Necker Hosp. 16:1987;307.
3. Calne R.Y., White D.J., Thiru S., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323.
4. Starzl T.E., Iwatsuki S., Malatack J.J., et al. Liver and kidney transplantation in children receiving cyclosporin A and steroids. J Pediatr. 100:1982;681.
5. Klare B., von Walter J., Hahn H., et al. Cyclosporin in renal transplantation in children. Lancet. 2:1984;692.
6. Offner G., Hoyer P.F., Brodehl J., et al. Cyclosporin A in paediatric kidney transplantation. Pediatr Nephrol. 1:1987;125.
7. Ettenger R.B., Rosenthal J.T., Marik J., et al. Factors influencing the improvement in cadaveric renal transplant survival in pediatric recipients. Transplant Proc. 21:1989;1693.
8. Ettenger R.B., Rosenthal J.T., Marik J.L., et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol. 5:1991;137.
9. Alexander S.R., Arbus G.S., Butt K.M., et al. The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 4:1990;542.
10. Tejani A., Sullivan E.K., Fine R.N., et al. Steady improvement in renal allograft survival among North American children a five-year appraisal by the North American Pediatric Renal Transplant Cooperative Study. Kidney Int. 48:1995;551.
11. Harmon W.E., Sullivan E.K. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int Suppl. 43:1993;S50.
12. Holt D.W., Fashola T.O., Johnston A. Monitoring cyclosporin is it still important? Immunol Lett. 29:1991;99.
13. Grevel J. Area-under-the-curve versus trough level monitoring of cyclosporine concentration critical assessment of dosage adjustment practices and measurement of clinical outcome. Ther Drug Monit. 15:1993;488.
14. Whitington P.F., Emond J.C., Whitington S.H., et al. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med. 322:1990;733.
15. Hoyer P.F., Brodehl J., Ehrich J.H., et al. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol. 5:1991;630.
16. Kahan B.D., Welsh M., Schoenberg L., et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 62:1996;599.
17. Mueller A.R., Platz K.P., Bechstein W.O., et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. Transplant Proc. 26:1994;3637.
18. Bokenkamp A., Offner G., Hoyer P.F., et al. Improved absorption of cyclosporin A from a new microemulsion formulation implications for dosage and monitoring. Pediatr Nephrol. 9:1995;196.
19. Kahan B.D., Dunn J., Fitts C., et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 59:1995;505.
20. Curtis J.J., Lynn M., Jones P.A. Neoral conversion from Sandimmune in maintenance renal transplant patients an individualized approach. J Am Soc Nephrol. 9:1998;1293.
21. Hoyer P.F. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Pediatr Transplant. 2:1998;35.
22. Levy G., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 73:2002;953.
23. Ault B.H., Honaker M.R., Osama Gaber A., et al. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol. 17:2002;815.
24. Nashan B., Cole E., Levy G., et al. Clinical validation studies of Neoral C(2) monitoring a review. Transplantation. 73:2002;S3.
25. Belitsky P., Mahalati K., West K., et al. Influence of drug formulation on utilization and outcomes Neoral and monitoring by sparse sample area under the curve. Transplant Proc. 31:1999;1667.
26. Mahalati K., Belitsky P., West K., et al. Approaching the therapeutic window for cyclosporine in kidney transplantation a prospective study. J Am Soc Nephrol. 12:2001;828.
27. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2:157, 2002.
28. Krankenpfl J: Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 72:1024, 2001.
29. Kelles A., Herman J., Tjandra-Maga T.B., et al. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant. 3:1999;282.
30. Dunn S.P. Neoral monitoring 2 hours post-dose and the pediatric transplant patient. Pediatr Transplant. 7:2003;25.
31. Melter M., Rodeck B., Kardorff R., et al. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. Transpl Int. 10:1997;419.
32. Hoyer P.F., Ettenger R., Kovarik J.M., et al. Everolimus in pediatric de nova renal transplant patients. Transplantation. 75:2003;2082.
33. Kahan B.D., Kramer W.G., Wideman C.A., et al. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc. 18:1986;115.
34. Katznelson S, Cecka JM: Immunosuppressive regimens and their effects on renal allograft outcome. Clin Transpl 361, 1996.
35. Benfield M.R., Stablein D., Tejani A. Trends in immunosuppressive therapy a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant. 3:1999;27.
36. Ryfel B, Mihatsch MJ: Cyclosporine nephrotoxicity. Toxicol Pathol 14:73, 1986.
37. Klintmalm G. Development of chronic renal cyclosporin-A toxicity. Nephrologie. 8:1987;131.
38. Mihatsch M.J., Steiner K., Abeywickrama K.H., et al. Risk factors for the development of chronic cyclosporine-nephrotoxicity. Clin Nephrol. 29:1988;165.
39. Messana J.M., Johnson K.J., Mihatsch M.J. Renal structure and function effects after low-dose cyclosporine in psoriasis patients a preliminary report. Clin Nephrol. 43:1995;150.
40. Niaudet P., Broyer M., Habib R. Serial renal biopsies in children with idiopathic nephrosis receiving cyclosporin. Contrib Nephrol. 114:1995;78.
41. Dieterle A., Gratwohl A., Nizze H., et al. Chronic cyclosporine- associated nephrotoxicity in bone marrow transplant patients. Transplantation. 49:1990;1093.
42. Gregory M.J., Smoyer W.E., Sedman A., et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome a clinical and histologic analysis. J Am Soc Nephrol. 7:1996;543.
43. Trompeter R., Fitzpatrick M., Hutchinson C., et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant. 7:2003;282.
44. David-Neto E., Lemos F.B., Furusawa E.A., et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol. 11:2000;343.
45. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 349:2003;931.
46. Ettenger R.B., Grimm E.M. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 38:2001;S22.
47. Van Damme-Lombaerts R., Webb N.A., Hoyer P.F., et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant. 6:2002;147.